Key facts
- This page summarizes Franklyn G. Prendergast's Form 4 filing for Immunome Inc. (IMNM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Oct 2023, 17:28.
Franklyn G. Prendergast - 02 Oct 2023 Form 4 Insider Report for Immunome Inc. (IMNM)
- Reporting relationship
- Director
- Issuer ticker
- IMNM
- Reported as of
- 02 Oct 2023
- Net transaction value
- +$185,929
- SEC form
- 4
- Accepted by SEC
- 04 Oct 2023, 17:28:38 UTC
- Prior SEC filing
- 12 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra Stoneman, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Franklyn G. Prendergast filed Form 4 for Immunome Inc. (IMNM) on 04 Oct 2023.
Change
- Previous filing in this sequence was filed on 12 Jun 2023.
- Current net transaction value: +$185,929.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMNM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +60,840
- Change %
- Price
- $0.000000
- Shares after
- 60,840
- Date
- 02 Oct 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMNM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $185,929
- Shares
- +137,725
- Change %
- Price
- $1.35*
- Shares after
- 137,725
- Date
- 02 Oct 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 137,725
- Exercise price
- $1.35
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.
Footnote F2
In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.